Renal cell carcinoma and proteomics

Renal cell carcinoma (RCC) represents 3% of adult malignancies. About 30% of RCC patients develop metastatic disease. So far, drugs cannot significantly increase the survival of these patients. We present a recent review of proteomics and RCC. Proteomic technologies have been used in the research to...

Full description

Saved in:
Bibliographic Details
Published inUrologia internationalis Vol. 84; no. 4; p. 373
Main Authors Sandim, Vanessa, Pereira, Denise A, Ornellas, Antonio A, Alves, Gilda
Format Journal Article
LanguageEnglish
Published Switzerland 01.01.2010
Subjects
Animals
Biomarkers, Tumor
Carcinoma, Renal Cell - diagnosis
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Early Detection of Cancer
Humans
Kidney Neoplasms - diagnosis
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Kidney Neoplasms - therapy
Neoplasm Proteins - metabolism
Precision Medicine
Predictive Value of Tests
Prognosis
Proteomics - methods
Online AccessGet more information

Cover

More Information
Summary:Renal cell carcinoma (RCC) represents 3% of adult malignancies. About 30% of RCC patients develop metastatic disease. So far, drugs cannot significantly increase the survival of these patients. We present a recent review of proteomics and RCC. Proteomic technologies have been used in the research to discover new markers of RCC that might increase survival. Furthermore, newly discovered markers cannot increase patient survival, rather their prognostic value supporting therapeutic decisions or new agents targeted at these new markers. More research is required to develop proteomic technologies and biomarkers for identification and validation.
ISSN:1423-0399
DOI:10.1159/000296283